NO2921489T3 - - Google Patents

Info

Publication number
NO2921489T3
NO2921489T3 NO13855534A NO13855534A NO2921489T3 NO 2921489 T3 NO2921489 T3 NO 2921489T3 NO 13855534 A NO13855534 A NO 13855534A NO 13855534 A NO13855534 A NO 13855534A NO 2921489 T3 NO2921489 T3 NO 2921489T3
Authority
NO
Norway
Application number
NO13855534A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2921489T3 publication Critical patent/NO2921489T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO13855534A 2012-11-13 2013-11-12 NO2921489T3 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012249792 2012-11-13
PCT/JP2013/080517 WO2014077235A1 (ja) 2012-11-13 2013-11-12 2-ピリドン化合物

Publications (1)

Publication Number Publication Date
NO2921489T3 true NO2921489T3 (zh) 2018-02-03

Family

ID=50731146

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13855534A NO2921489T3 (zh) 2012-11-13 2013-11-12

Country Status (26)

Country Link
US (1) US9695148B2 (zh)
EP (1) EP2921489B1 (zh)
JP (1) JP5963025B2 (zh)
KR (1) KR102160841B1 (zh)
CN (1) CN104768944B (zh)
AU (1) AU2013345930B2 (zh)
BR (1) BR112015010823A2 (zh)
CA (1) CA2891406C (zh)
DK (1) DK2921489T3 (zh)
ES (1) ES2641469T3 (zh)
HK (1) HK1207856A1 (zh)
HU (1) HUE034557T2 (zh)
IL (1) IL238701B (zh)
IN (1) IN2015DN03869A (zh)
MX (1) MX361479B (zh)
MY (1) MY173812A (zh)
NO (1) NO2921489T3 (zh)
NZ (1) NZ707832A (zh)
PH (1) PH12015501056A1 (zh)
PL (1) PL2921489T3 (zh)
PT (1) PT2921489T (zh)
RU (1) RU2662157C2 (zh)
SG (1) SG11201503716RA (zh)
TW (1) TWI591064B (zh)
WO (1) WO2014077235A1 (zh)
ZA (1) ZA201503323B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6048533B2 (ja) * 2014-05-12 2016-12-21 日産化学工業株式会社 2−ピリドン化合物を含有する医薬
KR20170003524A (ko) * 2014-05-13 2017-01-09 닛산 가가쿠 고교 가부시키 가이샤 2-피리돈 화합물의 제조 방법
WO2019228362A1 (zh) * 2018-05-31 2019-12-05 华领医药技术(上海)有限公司 含葡萄糖激酶激活剂和双胍类降糖药物的药物组合、组合物和复方制剂及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275069A (en) 1979-01-22 1981-06-23 The Upjohn Company Anti-diabetic 1,2-dihydro-2-oxo-6-alkyl-nicotinic acids
ATE278680T1 (de) 1999-03-29 2004-10-15 Hoffmann La Roche Glukokinase aktivatoren
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
PL2076502T3 (pl) 2006-06-08 2011-09-30 Lilly Co Eli Podstawione karboksyamidy jako antagoniści receptorów metabotropowych grupy I
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
TW200904439A (en) * 2007-07-17 2009-02-01 Bristol Myers Squibb Co Pyridone GPR119 G protein-coupled receptor agonists
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
TWI471132B (zh) * 2009-12-04 2015-02-01 大正製藥股份有限公司 2-吡啶酮化合物
JP2013010750A (ja) * 2011-06-02 2013-01-17 Taisho Pharmaceutical Co Ltd 2−ピリドン化合物を含有する医薬

Also Published As

Publication number Publication date
IN2015DN03869A (zh) 2015-10-02
EP2921489B1 (en) 2017-09-06
NZ707832A (en) 2019-03-29
IL238701A0 (en) 2015-06-30
KR20150082301A (ko) 2015-07-15
PT2921489T (pt) 2017-12-01
US20160289208A1 (en) 2016-10-06
WO2014077235A1 (ja) 2014-05-22
RU2015122717A (ru) 2017-01-10
HUE034557T2 (en) 2018-02-28
ZA201503323B (en) 2016-08-31
ES2641469T3 (es) 2017-11-10
PL2921489T3 (pl) 2018-01-31
JP5963025B2 (ja) 2016-08-03
EP2921489A4 (en) 2016-04-06
EP2921489A1 (en) 2015-09-23
AU2013345930A1 (en) 2015-06-04
SG11201503716RA (en) 2015-06-29
MX2015005884A (es) 2015-12-09
DK2921489T3 (en) 2017-10-16
MX361479B (es) 2018-12-06
CA2891406A1 (en) 2014-05-22
RU2662157C2 (ru) 2018-07-24
JPWO2014077235A1 (ja) 2017-01-05
KR102160841B1 (ko) 2020-09-28
IL238701B (en) 2018-10-31
HK1207856A1 (zh) 2016-02-12
MY173812A (en) 2020-02-24
AU2013345930B2 (en) 2017-08-24
BR112015010823A2 (pt) 2017-07-11
CA2891406C (en) 2021-03-16
TW201434826A (zh) 2014-09-16
CN104768944A (zh) 2015-07-08
TWI591064B (zh) 2017-07-11
CN104768944B (zh) 2017-03-29
US9695148B2 (en) 2017-07-04
PH12015501056B1 (en) 2015-07-27
PH12015501056A1 (en) 2015-07-27

Similar Documents

Publication Publication Date Title
BR112014017635A2 (zh)
BR112014017614A2 (zh)
BR112014017853A2 (zh)
BR112014017592A2 (zh)
BR112014017659A2 (zh)
BR112014017646A2 (zh)
BR112014017638A2 (zh)
AR092201A1 (zh)
BR112014017607A2 (zh)
BR112014020200A2 (zh)
BR112013027865A2 (zh)
BR112014024570A2 (zh)
BR112014017644A2 (zh)
BR112014017647A2 (zh)
BR112014017588A2 (zh)
BR112014017618A2 (zh)
BR112014013184A8 (zh)
BR112014017652A2 (zh)
BR112014017621A2 (zh)
BR112014017630A2 (zh)
BR112014017641A2 (zh)
BR112014019655A2 (zh)
BR112014017636A2 (zh)
BR112014019133A2 (zh)
BR112014017667A2 (zh)